We examined leukocyte counts and ex vivo cytokine response of whole blood to lipopolysaccharide (LPS) or lipoteichoic acid (LTA) in patients under low-dose molgramostim therapy. Patients were injected subcutaneously daily for ten days with 1 flglkg (n=9) or 2 flglkg (n=14) molgramostim. Leukocytosis was observed in all patients, but only the eosinophil fraction was significantly increased in relation to other leukocyte populations. Ex vivo IFN-y release was decreased and IL-IO and IL-lra secretion were increased in response to LPS or LTA. Thus, in non-neutropenic patients, leukocytosis can already be initiated by low doses of molgramostim. The ex vivo cytokine data suggest that these doses prime blood towards a systemic anti-inflammatory response.
release by monocytes, this high dose administered daily for two weeks did not affect the spontaneous release of these cytokines." In another study in cancer patients, one single dose (2.5, 5, or 10 ug/kg) of rhGM-CSF resulted in a significant increase of plasma levels of the anti-inflammatory mediator IL-l receptor antagonist (IL-lra) and a trend towards increased levels of the chemokine IL-8. 5 These observations combined with the relatively low incidence of inflammatory side effects reported in the several hundred thousand patients already treated with rhGM-CSF, led to the hypothesis that lower doses of rhGM-CSF might sufficeto initiate leukocytosis without exacerbating inflammation. In the context of a dose-finding study examining the potential of rhGM-CSF in wound healing," we tested this idea. Whole blood from rhGM-CSF treated patients was exposed to the bacterial components lipopolysaccharide (LPS) or lipoteichoic acid (LTA) ex vivo, so allowing the assessment of alterations of the humoral immune reaction without exposing patients to these stimuli."
RESULTS

Tolerability
In the group receiving 2 /lg/kgrhGM-CSF, 27 cases of side effects were recorded while there were only CYTOKINE, Vol. 12, No. 10 (October), 2000 : pp 1570 -1574 First publ. in: Cytokine 12 (2000 ), 10, pp. 1570 -1574 Konstanzer Leukocyte,collnts'; ,,
In ' both dosage groups, the .Ieukocyte .:count doubled ,by,day 2 and remained elevated above -basal values ( Fig.i : l) . .These . .changes , mainly -.reflected increases , in neutrophil-and monocyte counts. .Also, the eosinophil i count rose steadily, :reaching nine-fold initial values On dayIO: (Table 1 ).,
Spontaneous release of TNF-dand' IL-8iilcreased slightly on day 2 ( Fig. 2A 'and~) , but was slightly decreased when calculated per monocyte (Fig;2D) . Spontaneous IFN-y release was unchanged (Fig.,2 
.B):
, , In , patients' blood .stimulatediwith LPS, we obser-v'ed an initiaLincreas~ln::INF~arelease foilowed
by,,a decrease after prolongedjreatment, (Fig. 3A) ; Intracellular.TNF-n .measurementswith fluorescencelabelled anti-TNF-a antibodies.vin ol.Ps-stimulated blood detected only monocytes as producers ofTNF-a .
(data not shown). So, we calculated the release of TNF-a per million monocytes and found.rthis r.was unaltered throughout the study (Fig. 3B) , indicating that the .totalincrease-in TNF~a production stemmed from ' normal, ..competent . andnotpre-activatedcells. There 'wasa trend 'towards a decrease-in total IFN~y release ( Fig.3C ) and the productionof'Hxl~ (Fig: 3D ) onlyincreasedafter prolongedrh6MCSFtreatment; while' IL~8 ' or,IL-12 production were hardly affected (Fig; ,3E'andF) . 
DISCUSSION
'/ "
Although the molgramostim doses used were well below ' the .. recommended dosage-for cancer "patients (5-10 ug/kg' per day),"a substantialIeukocytosis-was recorded. The ;disproportionate .increase of theeosinephil .' . count :may be undesirab le' :,Accumulation .of eosinophilsand macrophages .afteradeneviral :expression of GIvI-CSF in rat lung was associated.with tissue LPS-stimulat.~d exvivo.release 9qL~lra (Fig.4A) .' . . inj ury .
• and fibrosis,S ,Ho.'!Vever, j n a " p atient with quadrupled by day 2 and remained elevated, G-CSF T-lymphocytosis,granulocyt6penia: and -severe periand IL~lO release ( Fig. 4B and C) increased transiently, anal infection, eosinophilia initiated by rhGM-CSF reflecting changesin monocyte counts. The secretion of treatment correlated with -improvement of the perianal IL-6 persisted significantly above basal levels (data not ulceration .
9 " , shown). ' ,' . " Other stu<.lieson CSF treatmerit1have meanwhile The lower ,dose of I1101grliwostim produced a . . sh,gwnt hat thech()sen limit 0[15,'090 leukocytes per III stronger trend toward an anti-inflammatory.profileof blood, was somewhat conservative. We also found cytokine release on stimulation: here, the concen-"that thenew'Ieukocytes were notpre-activated. One ug tration of IL-lO released was always greater and the and 2 ug/kg molgramostim pet: day were equipotent amount of IFN-y was always less, .
in . stimulating haematopoiesis while the l ug/kg , The ' cytokine rresponse to LTA ' corresponded group reported fewer side effe~ts Llndicating tharlow closely withthatdescribed :for ·LPS. The amounts qf doses of rhGM-CSF might be .more tolerable in non-TNF-u;' G-CSFandIL~lO r~lea:sed"weresimilaT with neutropenic patients while retaining desired effects. both stimuli, while lessIFN-'y' and more i:c.:8arid IL-6
The cytokine response pat!efutowaids inflammawereinducedby LTA. " . . , ;f tory stimuli ' offered unexpecte~rfesults: lowdoses of molgramostimpromoted an arid-tnflanlluatory profile, primingimmune cells:to produC~;1nore IL-IO, G-GSF and -Ils-Irarwhile release of prg:iriflammatoryTNF-u, IFN-and IL"'ll3' was not affecte~i9tslightlY :decreased. The distinct increase in Ilf6 release -may be-considered a protective reaction that is initiated sooner under molgramostim treatment.!" Notably; oytokinerelease onday2wasmot;diffetentinpatients who -dropped out of or who completed treatment. . ' GM"CSF ;was previously classed a. ; proinflammatory ' ,cytokine.".Now .it . appears -that ' the Release .of pro-inflammatory .cytokines by whole ••blood. of patients who received I ug/kgor 2 /lglkg molgramostimper. day, incubated With 10/lg!ml LPS for24 h. ThereleaseofTbllt-« calculated permonocyte is also shown (B).'A, TNF-a; C,IFN"y;n,IL-l~;E, IL"8; F, IL-12.
immunostimulatoryproperty. of rh.GM':CS~, 'i.e.
• its ability to recruit potent gJ;~nu1ocytes,and monocytes,.is already effected at low doses with relatively mild side effects, opening up new potential indications.
lll()rningso~d~ys 1,},3,S and,IQ before drug injection. Of the .group rece~ving 2 /lWkg n,}olgramostim, six patients withdrew from the study and. six patients were dismissed because their white blood cell count (WBC) rose above 15 OOO/Ill. In the I !!g/kg group, three patients were dismissed for this reason.
MATERIALS AND METHODS
Study design
Twenty-three patients of both sexes aged 40 to 85 who had a non-ulcerating basalioma of the face or neck removed by cryosurgery were enrolled into the open-label study. Patients received 2/!gIkg(1l=14) or Lug/kg (n=9) molgramostim (Leukomax'P, provided by ESSEX Pharma, Munich, Germany), subcutaneously for 10 days starting on the day of surgery. Blood samples were collected in the
Laboratory measurements
Automated differential WBC were performed. Five ml 20% whole blood in RPMIl640 (Biochrom, Berlin, Germany) supplemented with:4mM glutamine, 100 ID penicillin, 100 ug/ml streptomycin and 2.5 ID heparin (Hoffmann LaRoche, Grenzach~Whylen, Germany) was stimulated with 10 ug/ml LPS from Salmonella abortus equi or 10 /!g/ml LTA from Staphylococcus aureus (both Sigma, Deisenhofen, Germany). After 24 11-at 37°Cvials were shaken
